Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab PK/PD Study in Ulcerative Colitis with Loss of Response
NCT03182166Phase 2Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Nov 2017
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of golimumab in ulcerative colitis (UC), sponsored by CHU Saint-Etienne. Started Nov 2017; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03182166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182166.